Cam Gallagher - 04 Jan 2023 Form 4 Insider Report for Ocuphire Pharma, Inc. (IRD)

Role: Director
Signature: /s/ Emily J. Johns, by Power of Attorney
Issuer symbol: IRD
Transactions as of: 04 Jan 2023
Net transactions value: +$0.1574
Form type: 4
Filing time: 06 Jan 2023, 08:00:21 UTC
Previous filing: 15 Nov 2022
Next filing: 05 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCUP	Common Stock	Exercise of in-the-money or at-the-money derivative security	$0.1574	+1,574	+6.7%	$0.000100^*	24,928	04 Jan 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCUP	Series B Warrant (right to buy)	Exercise of in-the-money or at-the-money derivative security	$0	-1,574	-100%	$0.000000^*	0	04 Jan 2023	Common Stock	1,574	$0.000100	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The expiration date of the Series B Warrants occurred on the later of (x) the Reservation Date (as defined in the Series B Warrants) and (y) the date on which the Series B Warrants has been exercised in full.